Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 07, 2016 11:25 PM ET

Company Overview of Broad Institute of MIT and Harvard

Company Overview

7 Cambridge Center

Cambridge, MA 02142

United States





Key Executives for Broad Institute of MIT and Harvard

President and Founding Director
Age: 58
Associate Member and Director of Stanley Center for Psychiatric Research
Age: 74
Compensation as of Fiscal Year 2015.

Broad Institute of MIT and Harvard Key Developments

Transposagen, Inc. Licenses Broad Institute CRISPR/Cas9 Technology

Transposagen Inc. announced that it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. The CRISPR/Cas9 technology is incorporated into a suite of gene editing offerings that enable drug discovery researchers to create more accurate disease models, both in vitro and in vivo.

Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital

Neon Therapeutics announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline. The work of Neon Therapeutics co-founders Catherine J. Wu, M.D., at the Broad Institute and Dana-Farber Cancer Institute, Nir Hacohen, Ph.D., at the Broad Institute and Massachusetts General Hospital, and Ed Fritsch, Ph.D., at the Broad Institute and Dana-Farber Cancer Institute, led to the development of a personalized neoantigen vaccine, which is the foundation for Neon Therapeutics' proprietary lead compound, NEO-PV-01. The project was originated and led by the Broad Institute and was philanthropically funded in part by the Blavatnik Family Foundation. Dana-Farber Cancer Institute is currently enrolling two investigator-initiated trials with additional trials planned. Neon Therapeutics will build upon this research and initiate a company-sponsored clinical trial in 2016.

Beryllium Develops MCL-1 Platform for Structure-Guided Drug Discovery in Collaboration with the Broad Institute of MIT and Harvard

Beryllium announced the development of an MCL-1 platform for structure-guided drug discovery. MCL-1 is one of the top-ten most amplified genes in all of human cancer and is vital to tumor development and cancer progression. In collaboration with the Broad Institute of MIT and Harvard, scientists at Beryllium developed a crystallographic platform for MCL-1 that uses a combination of fusion protein and sequence engineering. Unlike previously available structures based on ligand dependent interactions, the new methods allow for systematic screening against MCL-1 and opens the door to structure based drug design.

Similar Private Companies By Industry

Company Name Region
K2 Finance Company, LLC United States
Alamo Group (SMC) Inc. United States
Tan Holdings Corporation United States
Lehigh Fuel Inc United States
Network Dealer Services, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Broad Institute of MIT and Harvard, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at